MHC molecules are proteins on the surface of your cells that act as a display system for the immune system, showing small fragments of proteins to passing immune cells so they can judge whether everything inside the cell is normal or something has gone wrong. “MHC” stands for major histocompatibility complex, and in humans these molecules go by another name you may have heard: HLA, or human leukocyte antigen. The system is far more than a simple alarm, though. MHC molecules shape which infections you fight well, which autoimmune diseases you’re susceptible to, whether a transplanted organ will be accepted, and even, according to some research, who you find attractive by scent.
Two Classes, Two Jobs
MHC molecules come in two main classical types, and the split between them is not arbitrary. Class I molecules sit on the surface of nearly every nucleated cell in your body. Their job is to display fragments of whatever proteins are being made inside the cell. If a virus has hijacked the cell’s machinery to churn out viral proteins, bits of those viral proteins get loaded onto class I molecules and carried to the surface. Killer T cells (also called cytotoxic T lymphocytes) patrol the body checking these displays. When a killer T cell’s receptor locks onto a viral fragment sitting in a class I molecule, it recognizes the cell as infected and destroys it.
Class II molecules have a narrower distribution. They appear mainly on specialized immune cells: dendritic cells, macrophages, and B cells. These are professional antigen-presenting cells whose role is to scoop up material from outside the cell, break it down, and present fragments of it on class II molecules. Helper T cells read these displays. When a helper T cell recognizes something foreign on a class II molecule, it kicks off a broader immune response, activating B cells to make antibodies and ramping up other arms of immunity.
The practical effect of this division is that class I lets the immune system monitor what’s happening inside cells, while class II lets it monitor what’s happening in the spaces between cells. Together they cover most threats.
How Class I Molecules Load Their Cargo
The peptide fragments displayed by class I molecules are short, typically eight to ten amino acids long.1PubMed. Degradation of cell proteins and the generation of MHC class I-presented peptides These fragments come mostly from proteins chopped up in the cell’s cytoplasm by a protein-recycling machine called the proteasome. Most of the peptides that end up on class I molecules aren’t from old, worn-out proteins. They’re actually generated from freshly made proteins, many of which are defective right off the ribosome. This matters because it means the class I pathway can alert killer T cells almost immediately after a virus begins making its proteins in a cell, rather than waiting hours for normal protein turnover to catch up.2PubMed Central. The MHC class I antigen presentation pathway: strategies for viral immune evasion
Once the proteasome generates these fragments, they need to get from the cytoplasm into the endoplasmic reticulum, a compartment inside the cell where class I molecules are being assembled. A dedicated transporter called TAP handles this shuttle service. Inside the endoplasmic reticulum, the peptide binds into a groove on the class I molecule. Only after a peptide fits properly does the class I molecule fold into its final shape and travel to the cell surface.3PubMed. Mechanisms of MHC class I–restricted antigen processing A fraction of the peptides generated by the proteasome escape complete destruction and make it through this pipeline; the rest are broken down entirely and recycled for other uses.1PubMed. Degradation of cell proteins and the generation of MHC class I-presented peptides
How Class II Molecules Load Theirs
Class II molecules take a different route. They’re assembled in the endoplasmic reticulum too, but they need to avoid grabbing peptides prematurely while still inside the cell. A chaperone protein called the invariant chain blocks the peptide-binding groove during assembly, essentially acting as a placeholder.4PubMed Central. Structural insights into human MHC-II association with invariant chain The class II molecule, still bound to its placeholder, then travels to a compartment where material swallowed from outside the cell has been broken down by enzymes. There, the placeholder fragment gets swapped out for an actual peptide from whatever the cell engulfed, whether that was a bacterium, a toxin, or a piece of dead cell. The loaded class II molecule then heads to the surface for inspection by helper T cells.
This system is elegant because it keeps class I and class II molecules sampling different pools of proteins. Class I reports on the cell’s internal state. Class II reports on what the cell has encountered in its environment. Killer T cells and helper T cells read different classes, so each branch of T cell immunity gets its own dedicated intelligence feed.
How T Cells Learn to Read MHC
T cells don’t come pre-programmed to work with MHC molecules. They have to be trained, and that training happens in the thymus, a small organ behind your breastbone. Developing T cells in the thymus are tested against self-peptide-MHC complexes displayed by specialized antigen-presenting cells positioned in different zones of the thymus.5PubMed Central. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see)
The process works like a two-round audition. In the first round, called positive selection, a developing T cell has to demonstrate that its receptor can actually bind to self-MHC molecules carrying normal self-peptides. T cells whose receptors can’t bind at all die by neglect. In the second round, negative selection, T cells whose receptors bind too strongly to self-peptide-MHC complexes are eliminated, because those cells would attack the body’s own tissues. T cells that react to self with moderate force can also be diverted into becoming regulatory T cells, which actively suppress immune responses rather than driving them.6PubMed Central. T-cell tolerance: central and peripheral The survivors are cells that can recognize MHC molecules but don’t react dangerously to the body’s own proteins.
When a T cell finally encounters an MHC molecule carrying a foreign peptide out in the body, it isn’t working alone. Co-receptors on the T cell surface also bind the MHC molecule to stabilize the interaction. CD8, the co-receptor on killer T cells, binds class I molecules with very low individual affinity but with extremely fast binding kinetics, much faster than the T cell receptor itself binds the peptide-MHC complex. This means CD8 can enhance recognition without overriding the specificity of the T cell receptor.7PubMed. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics
Natural Killer Cells and “Missing Self”
MHC molecules don’t just communicate with T cells. Natural killer (NK) cells use class I molecules in a completely different way. Instead of looking for foreign peptides, NK cells check whether class I molecules are present at all. Healthy cells display plenty of class I on their surface. When a virus or cancer causes a cell to lose its class I expression, NK cells notice the absence and kill the cell. This concept is called “missing self” recognition, and it was first described over 30 years ago.8PubMed Central. Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition
NK cells carry inhibitory receptors called KIRs that bind to specific class I molecules. When KIRs engage class I, the NK cell gets a “stand down” signal. When class I is missing or reduced, the inhibitory signal disappears and the NK cell attacks. The system is even more nuanced than a simple on-off switch. KIRs are sensitive not just to whether class I is present but to which peptides are loaded in it. During a viral infection or malignant transformation, the pool of peptides displayed on class I can shift even if the overall amount of class I stays the same. NK cells can detect these changes in the peptide repertoire and respond accordingly.9PubMed Central. Missing or altered self: human NK cell receptors that recognize HLA-C
NK cells that lack inhibitory KIRs matching the person’s own class I molecules aren’t absent from the body, but they are hyporesponsive. They carry a mature phenotype yet respond poorly to targets, including cells that are missing class I. By contrast, NK cells that do express a KIR matching self class I are functionally competent and ready to attack when that class I signal disappears.10Immunity. Shaping of Human NK Cell Antiviral Activity by MHC Class I Immune Receptors This calibration step ensures that “missing self” killing is targeted and doesn’t spiral into indiscriminate tissue damage.
Why MHC Genes Are the Most Diverse in the Human Genome
The genes encoding MHC molecules are the most polymorphic genes in the human genome, meaning they exist in more variant forms across the population than almost any other gene family. Thousands of different HLA alleles have been cataloged. This diversity is not random. Each variant of an MHC molecule has a slightly different peptide-binding groove, which means it can grab and display a slightly different set of pathogen-derived fragments. A population with many different MHC variants is harder for any single pathogen to evade, because even if a virus evolves to avoid detection by one MHC type, other people in the population carrying different types will still mount an effective response.
The practical consequences of this diversity are wide-ranging. Particular HLA alleles have been linked to susceptibility or resistance to infections including tuberculosis, HIV, hepatitis B and C, and COVID-19.11PubMed Central. Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections The flip side of this diversity is that it makes organ transplantation difficult. A transplanted organ carries the donor’s MHC molecules, and if those differ from the recipient’s, the recipient’s immune system treats the organ as foreign.
Transplant Rejection and HLA Matching
HLA matching between donor and recipient provides clear benefits in organ transplantation: better graft function, fewer rejection episodes, longer graft survival, and sometimes the ability to use less immunosuppressive medication. Mismatches lead to more frequent rejection, which in turn requires heavier immunosuppression that raises the risk of infections and cancers. Mismatches also sensitize the recipient, producing antibodies against the donor’s HLA types that can reduce the chances of finding a compatible organ for any future transplant.12PubMed Central. HLA Mismatching Strategies for Solid Organ Transplantation – A Balancing Act
In practice, perfect HLA matching is rare outside of identical twins. Modern transplant medicine balances the benefits of matching against the reality that waiting for a perfect match can mean waiting too long. Different organs also tolerate mismatches differently. The field has spent decades developing strategies to get the best possible match while minimizing the consequences of imperfect ones.
Autoimmune Diseases and Drug Reactions
Because MHC molecules determine which peptides get presented to T cells, the specific HLA types you carry can influence whether your immune system mistakenly attacks your own tissues. Some of the strongest genetic associations known in medicine are between particular HLA alleles and autoimmune diseases. HLA-B27 is linked to ankylosing spondylitis, a chronic inflammatory disease of the spine. HLA-DQ2 and HLA-DQ8 are strongly associated with celiac disease. HLA-DRB1 variants increase risk for rheumatoid arthritis, and HLA-DR3 and HLA-DR4 are tied to type 1 diabetes.13International Journal of Science and Research Archive. The link between HLA genes and autoimmune disease: A comprehensive review Having the associated allele doesn’t guarantee you’ll develop the disease, but it can dramatically shift the odds.
HLA type also matters for drug safety. Certain HLA alleles predispose carriers to severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening skin conditions triggered by specific medications. The connection is direct: the drug or its metabolite binds into the groove of a particular HLA molecule in an unusual way, stimulating a T cell response against the body’s own skin cells.14PubMed Central. A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine For a few high-risk drugs, HLA screening before prescribing is already standard clinical practice. The anticonvulsant carbamazepine, for example, is known to cause Stevens-Johnson syndrome in carriers of the HLA-B*15:02 allele, which is common in some Southeast Asian populations. Screening before prescribing this drug is recommended in those groups.
How Viruses Sabotage the System
Given how central MHC molecules are to immune detection, it’s no surprise that viruses have evolved elaborate strategies to interfere with them. Many viruses target the class I presentation pathway specifically, because class I is what flags infected cells for destruction by killer T cells. Viral immune evasion proteins can block almost every step in the pipeline: shutting down MHC synthesis at the gene level, degrading newly made MHC molecules before they reach the surface, blocking the TAP transporter so peptides can’t enter the endoplasmic reticulum, interfering with peptide editing in the loading complex, rerouting MHC molecules away from the cell surface, and accelerating the destruction of MHC molecules that do make it out.15PubMed Central. The race between viral immune evasion and the MHC class I antigen processing pathway
Herpesviruses are particularly adept at this. Cytomegalovirus alone encodes multiple proteins that target different stages of class I presentation, essentially hedging its bets. Other virus families have independently evolved their own sets of inhibitors targeting the same pathway, a striking example of convergent evolution driven by the selective pressure of immune surveillance.16PubMed. Viral immune evasion: Lessons in MHC class I antigen presentation But this strategy has a cost for the virus. Downregulating class I too aggressively triggers NK cell killing via the “missing self” mechanism described earlier. Viruses have to walk a fine line, reducing class I enough to dodge killer T cells without reducing it so much that NK cells notice.17PubMed Central. MHC-I pathway disruption by viruses: insights into immune evasion and vaccine design for animals
Cancer, Neoantigens, and Immunotherapy
Tumors face a similar dilemma to viruses. Cancer cells accumulate mutations, and some of those mutations produce altered proteins that the immune system hasn’t seen before. Fragments of these mutant proteins, called neoantigens, can be displayed on MHC molecules and recognized by T cells as foreign. This is the basis of the immune system’s natural anti-tumor surveillance, and it’s also the foundation for much of modern cancer immunotherapy.
Most of the early focus in immunotherapy was on neoantigens presented by class I molecules, which flag cancer cells for killing by cytotoxic T cells. But research has shown that class II-restricted neoantigens play their own distinct role in the anti-tumor response. Class II neoantigens activate helper T cells, which orchestrate a broader immune attack and may be critical for predicting which patients respond to checkpoint inhibitor therapy.18PubMed Central. MHC-II neoantigens shape tumour immunity and response to immunotherapy Both classes of neoantigen likely need to be considered when selecting patients for treatment or designing personalized cancer vaccines.
Non-Classical MHC Molecules and the Class III Region
Not all MHC molecules follow the classical pattern. A group of non-classical class I molecules has specialized roles beyond standard antigen presentation. The most studied of these is HLA-G, which is expressed almost exclusively by cells at the boundary between a pregnant woman’s uterus and the developing placenta. HLA-G interacts with receptors on the mother’s immune cells, including NK cells, T cells, and macrophages, suppressing immune responses that might otherwise reject the fetus as foreign tissue. It is widely considered a key factor in allowing successful pregnancy.19PubMed Central. HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance
Tucked between the class I and class II gene regions on chromosome 6 is a stretch of DNA called the class III region. Despite its name, it doesn’t encode MHC molecules at all. Instead, it contains genes for complement proteins (part of another arm of innate immunity) and a collection of genes involved in inflammation and RNA metabolism. Several of these genes encode RNA-binding proteins that regulate gene expression after transcription, and they’ve been linked to autoimmune diseases including systemic lupus erythematosus.20PubMed Central. MHC Class III RNA Binding Proteins and Immunity The class III region is a reminder that the MHC complex on chromosome 6 is more than just antigen-presentation genes. It’s a dense neighborhood of immune-related genes that happen to be inherited together, which is one reason specific HLA types correlate with so many different diseases.
MHC, Body Odor, and Mate Preference
One of the more surprising chapters in MHC research involves scent and mate choice. In the well-known “sweaty T-shirt” experiments, participants were asked to rate the pleasantness of T-shirts worn by strangers. The ratings correlated with MHC similarity between smeller and wearer. In people who were not using hormonal contraceptives, the scent of individuals with dissimilar MHC types was rated as more pleasant. Participants who were reminded of their own partner or ex-partner when sniffing a shirt turned out to share significantly fewer MHC alleles with that shirt’s wearer than you’d expect by chance.21PubMed Central. Body odour preferences in men and women: do they aim for specific MHC combinations or simply heterozygosity?
The interpretation is that these preferences would increase MHC diversity in offspring, giving them a broader set of MHC molecules and presumably a wider immune defense. The effect seems to be driven by overall MHC dissimilarity rather than preference for particular MHC combinations. Follow-up work has found some sex differences: men tended to prefer the scent of MHC-dissimilar individuals, while women’s preferences were more complex and may be influenced by cycle phase and by whether the wearer was MHC-heterozygous rather than simply dissimilar.22Behavioral Ecology. Major histocompatibility complex genes, symmetry, and body scent attractiveness in men and women The research is intriguing but the effects are modest, and nobody should start HLA-typing their dates.
An Ancient System With a 450-Million-Year History
MHC molecules are not a recent evolutionary invention. Comparative genomics in cartilaginous fish, the group that includes sharks and rays, has revealed a compact and highly organized MHC region containing class I genes alongside antigen-processing genes, class II genes linked to beta-2-microglobulin, non-classical class I lineages that are 450 million years old, and complement C4 genes. Analysis of how MHC-related genes are distributed across chromosomes in early-branching vertebrate lineages suggests that both class I and class II genes arose after two rounds of whole-genome duplication early in vertebrate evolution.23PubMed Central. An Ancestral Major Histocompatibility Complex Organization in Cartilaginous Fish: Reconstructing MHC Origin and Evolution
The fact that the same basic architecture persists from sharks to humans speaks to how central this system is. Adaptive immunity as we know it, with T cells checking MHC displays and mounting targeted responses, appears to have been locked in place before vertebrates diversified into the groups we see today. The extraordinary polymorphism of MHC genes has been maintained by natural selection across this entire span, driven by the relentless arms race between hosts and the pathogens trying to evade their immune systems.